Related Experiment Video
Updated: Jun 13, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy
Stephen L Abrams1, Linda S Steelman, John G Shelton
1Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, USA.
Abstract:
The effects of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways on proliferation, drug resistance, prevention of apoptosis and sensitivity to signal transduction inhibitors were examined in FL/DeltaAkt-1:ER*(Myr(+)) + DeltaRaf-1:AR cells which are conditionally-transformed to grow in response to Raf and Akt activation. Drug resistant cells were isolated from FL/DeltaAkt-1:ER*(Myr(+)) + DeltaRaf-1:AR cells in the presence of doxorubicin. Activation of Raf-1, in the drug resistant FL/DeltaAkt-1:ER*(Myr(+)) + DeltaRaf-1:AR cells, increased the IC(50) for doxorubicin 80-fold, whereas activation of Akt-1, by itself, had no effect on the doxorubicin IC50. However, Akt-1 activation enhanced cell proliferation and clonogenicity in the presence of chemotherapeutic drugs. Thus the Raf/MEK/ERK pathway had profound effects on the sensitivity to chemotherapeutic drugs, and Akt-1 activation was required for the long term growth of these cells as well as resistance to chemotherapeutic drugs. The effects of doxorubicin on the induction of apoptosis in the drug resistant cells were enhanced by addition of either mTOR and MEK inhibitors. These results indicate that targeting the Raf/MEK/ERK and PI3K/Akt/mTOR pathways may be an effective approach for therapeutic intervention in drug resistant cancers that have mutations activating these cascades.
Insights
Targeting the Raf/MEK/ERK and PI3K/Akt/mTOR pathways may treat drug-resistant cancers. The Raf/MEK/ERK pathway significantly impacts drug sensitivity, while Akt-1 is crucial for long-term growth and resistance.
Area of Science:
- Cellular signaling pathways
- Cancer biology
- Drug resistance mechanisms
Background:
- The Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways regulate critical cellular processes.
- Understanding these pathways is vital for cancer therapy.
Purpose of the Study:
- To investigate the role of Raf/MEK/ERK and PI3K/Akt/mTOR pathways in drug resistance.
- To examine their effects on cell proliferation, apoptosis, and sensitivity to inhibitors.
Main Methods:
- Utilized FL/DeltaAkt-1:ER*(Myr(+)) + DeltaRaf-1:AR cells, conditionally transformed for growth upon Raf and Akt activation.
- Isolated drug-resistant cells by exposing cells to doxorubicin.
- Assessed IC50 values for doxorubicin and evaluated effects of pathway activation and inhibition.
Main Results:
- Raf-1 activation increased doxorubicin IC50 80-fold in resistant cells; Akt-1 activation alone had no effect on IC50.
- Akt-1 activation enhanced proliferation and clonogenicity in the presence of chemotherapeutic drugs.
- Doxorubicin-induced apoptosis in resistant cells was enhanced by mTOR and MEK inhibitors.
Conclusions:
- The Raf/MEK/ERK pathway profoundly influences sensitivity to chemotherapeutic drugs.
- Akt-1 activation is essential for long-term growth and drug resistance.
- Targeting these signaling pathways offers a potential therapeutic strategy for drug-resistant cancers with activating mutations.
More Related Videos
Related Concept Videos
MAPK Signaling Cascades
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Mitogens and the Cell Cycle
Treatment Resistant Cancers
Master Transcription Regulators

